This inventor holds 2 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 3 EPO patents. Top assignees: Friedrich-Alexander-Universitat Erlangen-Nürnberg, Ludwig-Maximilians-Universitat München. Active years: 2022-2024.
Location History:
- Achmühle, DE (2022)
- Achmuhle, DE (2024)
Company Filing History:
1 out of 116 
1 out of 50 Years Active: 2022-2024
Title: Nadja Fenn: Innovator in Myeloid Targeting and Tumor Therapy
Introduction
Nadja Fenn is a prominent inventor based in Achmühle, Germany. She has made significant contributions to the field of biomedical research, particularly in the development of innovative therapeutic molecules. With a total of 2 patents, her work focuses on targeting specific cells involved in acute myeloid leukemia and myelodysplastic syndrome.
Latest Patents
Nadja Fenn's latest patents include groundbreaking inventions. The first patent is for a CD33-, CD16- and CD123-specific single chain triplebody. This invention relates to a nucleic acid molecule capable of specifically binding to CD33, CD16, and CD123. It includes various components such as a nucleic acid molecule encoding a protein and a vector comprising the nucleic acid molecule. This invention has potential applications in treating acute myeloid leukemia and myelodysplastic syndrome.
The second patent is for a trispecific molecule that combines specific tumor targeting with local immune checkpoint inhibition. This novel molecule features three binding sites, each with specificity for a tumor cell, an effector cell, and a checkpoint molecule. The patent also covers pharmaceutical compositions that utilize this innovative molecule.
Career Highlights
Nadja Fenn has worked at prestigious institutions, including Friedrich-Alexander-Universität Erlangen-Nürnberg and Ludwig-Maximilians-Universität München. Her academic background and research experience have significantly contributed to her innovative work in the field of cancer therapy.
Collaborations
Throughout her career, Nadja has collaborated with notable colleagues, including Karl-Peter Hopfner and Georg H. Fey. These collaborations have further enhanced her research and development efforts.
Conclusion
Nadja Fenn is a trailblazer in the field of biomedical innovation, with a focus on myeloid targeting and tumor therapy. Her patents reflect her commitment to advancing medical science and improving treatment options for patients.